Open Nav

Invirsa, Inc.

  • Isaiah Shalwitz, Invirsa


  • Date:Thursday, October 18
  • Time:9:15 AM - 9:30 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Invirsa has discovered the potential of a naturally occurring molecule that is key to the coordinated immune response to infection. Not only does it activate pathways to reduce viral replication, but it also works to reduce excess inflammation, while enhancing the wound healing response. The effects on inflammation and wound healing are very important since the viral injury continues well after the virus is cleared. INV-102's lead indication is viral (adenovirus) conjunctivitis, for which there are no approved therapeutics. However, the greater potential is infectious respiratory disease where we have already demonstrated POC in RSV. There is no other small molecule that reduces both DNA (adenovirus) and RNA (RSV) viral activity, while simultaneously reducing excess inflammation and repairing injury. Invirsa strongly believes that INV-102 is an ideal first line therapeutic for ophthalmic and respiratory disease and recovery.
  • Company
  • Company HQ City:Columbus, OH
  • Company HQ Country:United States
  • Company HQ State:Ohio                              
  • CEO/Top Company Official:Robert Shalwitz
  • Year Founded:2016
  • Main Therapeutic Focus:Infectious Diseases
  • Lead Product in Development :INV-102
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Additional Information/Comments:There is no other wound healing/inflammatory compound that also reduces viral replication.
  • Previous and Current Investors:Cincytech, Rev1
  • Size of Last Investment Round:$620,000
  • Total Amount Raised to Date, In All Rounds:$720,000
Isaiah Shalwitz